Venous plasma serotonin is not a proper biomarker for pulmonary arterial hypertension

Figures & data

Table I. Patients’ characteristics.

No. patient	Age years	Sex	PAH etiology	MPAP mmHg	PVR WU	MRAP mmHg	CO L/min	PCWP mmHg	NT-proBNP ng/L	Medications	NYHA	Serotonin ng/ml
1	76	F	Systemic sclerosis	*Missing value						Bosentan ASA	II	9.96
2	51	F	HIV	*Missing value						Bosentan Sildenafil	II	6.90
3	36	F	IPAH	64	18.4	3	3.2	5	3478	Ambrisentan Sildenafil ASA	II	4.18
4	79	F	Systemic sclerosis	50	8.8	3	4.9	7		Bosentan ASA	II	8.60
5	48	F	IPAH	39	7.5	4	3.6	12	170	Ambrisentan Sildenafil ASA	I	41.05
6	65	F	IPAH	57	12.2	4	4.1	7	169	Bosentan Sildenafil	II	11.61
7	44	M	IPAH	61	10.4	2	5.38	5	247	Bosentan Sildenafil ASA	III	7.21
8	64	F	IPAH	36	7.4	2	4.2	5	1202	Bosentan ASA	II	4.49
9	43	M	IPAH	50	9.8	2	4.6	5		Bosentan ASA	II	8.72

F, female; M, male; IPAH, idiopathic pulmonary arterial hypertension; PVR, pulmonary vascular resistance; CO, cardiac output; MRAP, mean right atrial pressure; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; ASA, acetylsalicylic acid; NYHA, New York Heart association functional classification; PCW, pulmonary capillary wedge pressure.

*SPAP, systolic pulmonary arterial pressure measured by echocardiography is 60 and 102 respectively.

Figure 1. Serotonin (A) and β-thromboglobulin (B) concentrations measured in platelet-poor plasma from healthy controls and in patients with pulmonary arterial hypertension (PAH): median (line) and interquartile range (box).